Ocular Aesthetics, LLC dba Ocular Clinical Trials
Of the 140 million contact lens (CL) wearers worldwide, most wear soft contact lenses. Despite major improvements in contact lens care, nearly 20% of wearers stop using lenses, with contact lens discomfort (CLD) being the main reason. This study aims to determine whether VEVYE, a water-free 0.1% cyclosporine ophthalmic solution indicated for the treatment of DED, can improve contact lens comfort in people with dry eye disease.
This is a 12-week, three-visit study aims to evaluate whether VEVYE, a water-free 0.1% cyclosporine ophthalmic solution indicated for the treatment of dry eye disease (DED), can alleviate DED symptoms and improve contact lens (CL) comfort. The open-label, prospective clinical trial will recruit 50 individuals who meet the study's eligibility criteria.
Inclusion Criteria: * Adult male and female subjects of any race or ethnicity who are ≥18 years of age. * Best corrected CL visual acuity of 0.3 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/40). * Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs). * Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores (CLDEQ-8 scores ≥ 12). * A VAS score of ≥40 for Eye Dryness and End of Day Contact Lens Discomfort. * A corneal fluorescein staining score on the original NEI scale of ≥3. * Habitually wears soft CLs fo…
Participants will be treated with VEVYE (water-free cyclosporine 0.1% ophthalmic solution) twice per day in each eye before and after contact lens use.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.